These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6584648)

  • 1. [Low dose Ara-C for remission induction in aged patients with atypical nonlymphocytic leukemia and refractory anemia with excess blasts].
    Sawada H; Yamagishi M; Mochizuki T; Ishikura H; Izumi Y; Park YH; Wano M; Usui T; Uchino H
    Rinsho Ketsueki; 1983 Nov; 24(11):1464-72. PubMed ID: 6584648
    [No Abstract]   [Full Text] [Related]  

  • 2. [Small-dose cytarabine (Ara-C) in the treatment of myelodysplastic syndrome].
    Dan K; Ogata K; Gomi S; Ohki I; Kuwabara T; Horikoshi H; Nomura T
    Rinsho Ketsueki; 1984 Oct; 25(10):1600-5. PubMed ID: 6596446
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical effect of low dose ara-C in twenty patients with acute nonlymphocytic leukemia, atypical leukemia, and refractory anemia with excess of blasts.
    Izumi Y; Sawada H; Okazaki T; Mochizuki T; Ishikura H; Tashima M; Yamagishi M; Uchino H; Usui T; Akasaka S
    Nihon Ketsueki Gakkai Zasshi; 1986 Feb; 49(1):93-100. PubMed ID: 3705895
    [No Abstract]   [Full Text] [Related]  

  • 4. [Preliminary results of the treatment of non-lymphoblastic leukemia and bone marrow dysplasia with small doses of cytosine arabinoside].
    Brodzki LM
    Acta Haematol Pol; 1985; 16(1-2):85-9. PubMed ID: 3914171
    [No Abstract]   [Full Text] [Related]  

  • 5. Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
    Satou Y; Kubota T; Yonekura S; Noguchi K; Oobayashi Y; Nagao T; Arimori S
    Tokai J Exp Clin Med; 1986 Oct; 11(4):249-54. PubMed ID: 3617109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aplastic anemia which terminated in hypoplastic leukemia 10 years after diagnosis].
    Nishii K; Katayama N; Komada F; Kageyama S; Hoshino K; Tsukada T; Nishikawa M; Kobayashi T; Minami N; Shirakawa S
    Rinsho Ketsueki; 1990 Sep; 31(9):1523-6. PubMed ID: 2174086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute nonlymphocytic leukemia and acute aplastic anemia. The simultaneous occurrence in marital partners.
    Stewart FM; Hess CE
    Arch Intern Med; 1983 Jun; 143(6):1156-8. PubMed ID: 6574728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    HoĊ‚owiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
    Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia.
    Jehn U; De Bock R; Haanen C
    Blut; 1984 May; 48(5):255-61. PubMed ID: 6586211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
    Yamato H; Yamada K; Koike T; Yoshida M; Tsunogake S; Aoyagi M; Nakamura Y; Watanabe K; Saito K; Enokihara H
    Rinsho Ketsueki; 1995 Feb; 36(2):128-33. PubMed ID: 7536277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
    Kumagawa M; Suzuki K; Nagano M; Takamatsu Y; Suzumiya J; Tamura K
    Rinsho Ketsueki; 2003 Jun; 44(6):404-6. PubMed ID: 12884821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Low-dose cytosine arabinoside (ARA-C) in the treatment of acute myeloid leukemia].
    Beris P; Rieder A; Andrey C; Helg C; Chapuis B
    Schweiz Med Wochenschr; 1984 Dec; 114(48):1763-6. PubMed ID: 6596706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Yamauchi T; Negoro E; Arai H; Ikegaya S; Takagi K; Takemura H; Inai K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2007; 27(4C):2635-9. PubMed ID: 17695426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 20. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.